engleski

MMP-9 and TIMP-1 concentrations in plasma of patients with chronic obstructive pulmonary disease

Background: An imbalance of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) has been implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). The aim of this study was to evaluate MMP-9 and TIMP-1 concentrations in COPD patients in relation to the severity of disease. Materials and methods: The study included patients with stable COPD (N=59) and healthy volunteers (N=21). COPD patients were divided into subgroups (GOLD stages II to IV) according to the spirometry results. Plasma MMP-9 and TIMP-1 concentrations were determined using a commercially available ELISA kits. Classic inflammatory markers were also measured (differential leukocyte counts and CRP). Results: MMP-9 concentration in COPD patients (204.13 (115.70-351.24) ng/mL) was significantly increased comparing to healthy controls (70.25 (52.48-104.96) ng/mL) with P<0.001. There were no significant differences in TIMP-1 concentration. MMP-9/TIMP-1 ratio differed significantly between COPD patients (1.659 (0.965-2.687)) and healthy controls (0.627 (0.424-0.890)) with P<0.001. Similar pattern was found already in GOLD II stage of disease. Very good diagnostic accuracy for MMP-9 was determined (AUC=0.884 ; sensitivity of 66.1% and specificity of 100.0% ; P<0.0001). The multivariate logistic regression model showed that the use of MMP-9 in combination with neutrophils, lymphocytes and CRP improved significantly (P=0.0232) diagnostic strength (AUC=0.975). Conclusions: Increased concentration of MPP-9 and higher MMP-9/TIMP-1 ratio found in COPD patients as early as in GOLD II stage highlight the significance of protease/antiprotease imbalance for the development of COPD and potential use of these parameters as biomarkers for early diagnosis of COPD.

MMP-9 ; TIMP-1 ; chronic obstructive pulmonary disease

nije evidentirano